DK3231444T3 - Ny behandling - Google Patents

Ny behandling Download PDF

Info

Publication number
DK3231444T3
DK3231444T3 DK17174446.9T DK17174446T DK3231444T3 DK 3231444 T3 DK3231444 T3 DK 3231444T3 DK 17174446 T DK17174446 T DK 17174446T DK 3231444 T3 DK3231444 T3 DK 3231444T3
Authority
DK
Denmark
Prior art keywords
new treatment
treatment
new
Prior art date
Application number
DK17174446.9T
Other languages
English (en)
Inventor
Katharine Abbott-Banner
John Hanrahan
David Thomas
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1408384.4A external-priority patent/GB201408384D0/en
Priority claimed from GBGB1417719.0A external-priority patent/GB201417719D0/en
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Application granted granted Critical
Publication of DK3231444T3 publication Critical patent/DK3231444T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17174446.9T 2014-05-12 2015-05-11 Ny behandling DK3231444T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1408384.4A GB201408384D0 (en) 2014-05-12 2014-05-12 New treatment
GBGB1417719.0A GB201417719D0 (en) 2014-10-07 2014-10-07 New treatment
EP15724354.4A EP3142701B1 (en) 2014-05-12 2015-05-11 New treatment

Publications (1)

Publication Number Publication Date
DK3231444T3 true DK3231444T3 (da) 2020-03-16

Family

ID=53264683

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15724354.4T DK3142701T3 (da) 2014-05-12 2015-05-11 Ny behandling
DK17174446.9T DK3231444T3 (da) 2014-05-12 2015-05-11 Ny behandling

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15724354.4T DK3142701T3 (da) 2014-05-12 2015-05-11 Ny behandling

Country Status (16)

Country Link
US (2) US10864213B2 (da)
EP (2) EP3231444B1 (da)
AU (1) AU2015261239B2 (da)
CA (1) CA2948620C (da)
CY (2) CY1120550T1 (da)
DK (2) DK3142701T3 (da)
ES (2) ES2773142T3 (da)
HU (1) HUE048020T2 (da)
IL (1) IL248856B (da)
MX (1) MX377387B (da)
PL (2) PL3231444T3 (da)
PT (2) PT3142701T (da)
RU (1) RU2688191C2 (da)
SI (2) SI3142701T1 (da)
WO (1) WO2015173551A1 (da)
ZA (1) ZA201607705B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
PT3332767T (pt) 2014-09-15 2019-06-27 Verona Pharma Plc Formulação por inalação líquida compreendendo rpl554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
GB2578093B (en) * 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
WO2021133782A1 (en) * 2019-12-26 2021-07-01 National Jewish Health Methods of treating cystic fibrosis transmembrane conductance regulator (cftr) dysfunction
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
WO2025093848A1 (en) 2023-11-01 2025-05-08 Verona Pharma Plc Ensifentrine for treating bronchiectasis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DK0617610T3 (da) 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
DK1073417T3 (da) 1998-04-18 2003-03-24 Glaxo Group Ltd Farmaceutisk aerosolformulering
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
CA2368413C (en) 1999-03-31 2008-07-29 Verona Pharma Plc Derivatives of pyrimido[6,1-a]isoquinolin-4-one
ES2193069T3 (es) 1999-04-14 2003-11-01 Glaxo Group Ltd Formulacion farmaceutica en aerosol.
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
DK2365972T3 (da) 2008-11-06 2015-01-19 Vertex Pharma Modulatorer af atp-bindende kassettetransportører
EP2993178A1 (en) 2009-09-11 2016-03-09 CHIESI FARMACEUTICI S.p.A. Glucocorticoid condensed in position 16,17 with an isoxazolidine group
PT2603509E (pt) * 2010-08-09 2014-08-29 Verona Pharma Plc Forma cristalina de um composto pirimidio[6,1-a]isoquinolin-4-ona
WO2012069275A1 (en) 2010-11-26 2012-05-31 Chiesi Farmaceutici S.P.A. Glycine derivatives and their use as muscarinic receptor antagonists
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
CA2845039A1 (en) * 2011-08-18 2013-02-21 Shire Ag Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN105229547A (zh) 2013-03-14 2016-01-06 林肯环球股份有限公司 导出或者使用针对外部系统的焊接定序器数据的系统和方法
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
PT3332767T (pt) 2014-09-15 2019-06-27 Verona Pharma Plc Formulação por inalação líquida compreendendo rpl554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition

Also Published As

Publication number Publication date
DK3142701T3 (da) 2018-08-13
EP3231444A1 (en) 2017-10-18
US10864213B2 (en) 2020-12-15
WO2015173551A1 (en) 2015-11-19
RU2016148447A3 (da) 2018-12-27
US20210106585A1 (en) 2021-04-15
US11759467B2 (en) 2023-09-19
ZA201607705B (en) 2020-05-27
IL248856B (en) 2020-07-30
CY1120550T1 (el) 2019-07-10
PL3231444T3 (pl) 2020-05-18
CY1122748T1 (el) 2021-03-12
EP3142701B1 (en) 2018-06-27
CA2948620C (en) 2023-01-24
SI3142701T1 (en) 2018-08-31
PT3231444T (pt) 2020-03-05
SI3231444T1 (sl) 2020-04-30
MX2016014756A (es) 2017-03-23
EP3142701A1 (en) 2017-03-22
US20170112839A1 (en) 2017-04-27
RU2688191C2 (ru) 2019-05-21
MX377387B (es) 2025-03-10
CA2948620A1 (en) 2015-11-19
HUE048020T2 (hu) 2020-05-28
PT3142701T (pt) 2018-10-18
ES2682105T3 (es) 2018-09-18
ES2773142T3 (es) 2020-07-09
AU2015261239B2 (en) 2020-02-27
AU2015261239A1 (en) 2016-12-01
RU2016148447A (ru) 2018-06-19
IL248856A0 (en) 2017-01-31
EP3231444B1 (en) 2019-12-18
PL3142701T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3171891T3 (da) Fremgangsmåde
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da) Karadgang
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da) Forstøver
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
HUE046894T2 (hu) Anamorelinen alapuló gyógyászati kezelések
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
IL252086A0 (en) Novel methods
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE202014005655U8 (de) llluminationsvorrichtung
DK3250168T3 (da) Forbedringer vedrørende nethindebehandling
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer